Raymond James set a $10.00 price target on IMV (NYSE:IMV) in a research report released on Thursday, BayStreet.CA reports. The firm currently has an outperform rating on the stock.
A number of other research firms have also recently commented on IMV. Zacks Investment Research cut shares of IMV from a buy rating to a hold rating in a report on Saturday, October 26th. HC Wainwright set a $11.50 price target on shares of IMV and gave the stock a buy rating in a report on Monday, September 30th. Finally, Wells Fargo & Co assumed coverage on shares of IMV in a report on Monday, October 28th. They issued a market perform rating for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. IMV currently has an average rating of Buy and a consensus target price of $8.94.
Shares of IMV traded down $0.30 during trading hours on Thursday, hitting $2.58. 8,241 shares of the stock were exchanged, compared to its average volume of 19,864. IMV has a fifty-two week low of $2.25 and a fifty-two week high of $7.07. The business has a 50-day moving average of $2.74 and a 200-day moving average of $3.15.
IMV (NYSE:IMV) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.03). The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.05 million.
A number of large investors have recently bought and sold shares of IMV. Citadel Advisors LLC bought a new position in shares of IMV in the second quarter valued at $37,000. Hartford Financial Management Inc. lifted its stake in shares of IMV by 9.6% in the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after buying an additional 3,348 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock valued at $260,000 after buying an additional 13,228 shares in the last quarter. Morgan Stanley lifted its stake in shares of IMV by 260.5% in the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock valued at $264,000 after buying an additional 65,300 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of IMV by 3.6% in the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock valued at $288,000 after buying an additional 3,453 shares in the last quarter.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Featured Story: The components of the Stochastic Momentum Index
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.